Effects of Bifidobacterium triple viable powder combined with Meropenem in treatment of neonatal necrotizing enterocolitis
Objective:To observe effects of Bifidobacterium triple viable powder combined with Meropenem in treatment of neonatal necrotizing enterocolitis(NEC).Methods:A prospective study was conducted on 116 children with NEC admitted to the hospital from October 2020 to November 2022.According to the random number table method,they were divided into study group and control group,58 cases in each group.The control group was treated with Meropenem,while the study group was treated with Bifidobacterium triple viable powder on the basis of that of the control group.The clinical efficacy,the improvement time of clinical symptoms,the levels of inflammatory factors[C-reactive protein(CRP),procalcitonin(PCT)and interleukin-10(IL-10)],the levels of intestinal flora distribution indexes,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the study group was 89.66%(52/58),which was higher than 75.86%(44/58)of the control group,and the difference was statistically significant(P<0.05).The vomiting relief time,the abdominal distension relief time,and the stool character and frequency recovery time in the study group were shorter than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CRP,PCT and IL-10 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total number of bacilli,the total number of cocci and the ratio of bacilli to cocci in the two groups were higher than those before the treatment,and those in the study group were higher than the control group,the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Bifidobacterium triple viable powder combined with Meropenem in the treatment of the children with NEC can improve the total effective rate of treatment,shorten the improvement time of clinical symptoms,improve the levels of intestinal flora distribution indexes,and reduce the levels of inflammatory factors.Moreover,it is superior to single Meropenem treatment.
NETL
NSTL
万方数据
